ME03498B - Individualizovane vakcine protiv kancera - Google Patents

Individualizovane vakcine protiv kancera

Info

Publication number
ME03498B
ME03498B MEP-2019-237A MEP2019237A ME03498B ME 03498 B ME03498 B ME 03498B ME P2019237 A MEP2019237 A ME P2019237A ME 03498 B ME03498 B ME 03498B
Authority
ME
Montenegro
Prior art keywords
cancer
individualized vaccines
individualized
vaccines
Prior art date
Application number
MEP-2019-237A
Other languages
German (de)
English (en)
French (fr)
Inventor
Ugur Sahin
Michael Koslowski
Tana Omokoko
Sebastian Kreiter
Mustafa Diken
Jan Diekmann
Cedrik Britten
John Castle
Martin Löwer
Bernhard Renard
Graaf Johannes Hendrikus De
Original Assignee
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50185364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03498(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/002576 external-priority patent/WO2012159643A1/en
Application filed by Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh, Biontech Rna Pharmaceuticals Gmbh filed Critical Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority claimed from PCT/EP2012/002209 external-priority patent/WO2012159754A2/en
Publication of ME03498B publication Critical patent/ME03498B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
MEP-2019-237A 2011-05-24 2012-05-23 Individualizovane vakcine protiv kancera ME03498B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2011/002576 WO2012159643A1 (en) 2011-05-24 2011-05-24 Individualized vaccines for cancer
EP2012000006 2012-01-02
EP12723117.3A EP2714071B1 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer
PCT/EP2012/002209 WO2012159754A2 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer

Publications (1)

Publication Number Publication Date
ME03498B true ME03498B (me) 2020-04-20

Family

ID=50185364

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-237A ME03498B (me) 2011-05-24 2012-05-23 Individualizovane vakcine protiv kancera

Country Status (8)

Country Link
EP (4) EP3473267B1 (me)
CY (3) CY1122110T1 (me)
DK (1) DK3473267T3 (me)
HR (1) HRP20191535T1 (me)
ME (1) ME03498B (me)
PL (2) PL2714071T3 (me)
RS (1) RS59369B1 (me)
SI (1) SI2714071T1 (me)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2714071T3 (da) 2011-05-24 2019-09-16 Biontech Rna Pharmaceuticals Gmbh Individualiserede vacciner mod cancer
PL2714071T3 (pl) 2011-05-24 2019-12-31 Biontech Rna Pharmaceuticals Gmbh Zindywidualizowane szczepionki przeciwrakowe
EP3881324A1 (en) * 2018-11-15 2021-09-22 Nouscom AG Selection of cancer mutations for generation of a personalized cancer vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
AU1774299A (en) 1997-12-24 1999-07-19 Imperial Cancer Research Technology Limited Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
PT1214097E (pt) 1999-09-16 2009-10-19 Eisai Inc Ácidos nucleicos que codificam polipéptidos de poliepitopos
EP1392341B1 (de) * 2001-06-05 2005-03-30 Curevac GmbH Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
CN100392087C (zh) * 2001-11-26 2008-06-04 昆士兰大学 黄病毒疫苗输送系统
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003235707A1 (en) 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
DE10335833A1 (de) * 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP3699266A1 (en) * 2010-05-14 2020-08-26 The General Hospital Corporation Neoantigen specific cytotoxic t cells for use in treating cancer
PL2714071T3 (pl) 2011-05-24 2019-12-31 Biontech Rna Pharmaceuticals Gmbh Zindywidualizowane szczepionki przeciwrakowe

Also Published As

Publication number Publication date
HRP20191535T1 (hr) 2019-11-29
EP3892295A1 (en) 2021-10-13
SI2714071T1 (sl) 2019-11-29
RS59369B1 (sr) 2019-11-29
EP4223311A1 (en) 2023-08-09
CY1122110T1 (el) 2020-11-25
EP3473267B1 (en) 2021-09-08
EP3892295B1 (en) 2023-04-26
EP2714071A2 (en) 2014-04-09
CY1126128T1 (el) 2023-11-15
CY1124685T1 (el) 2022-07-22
EP3473267A1 (en) 2019-04-24
PL3473267T3 (pl) 2022-01-10
PL2714071T3 (pl) 2019-12-31
EP2714071B1 (en) 2019-07-10
DK3473267T3 (da) 2021-10-18

Similar Documents

Publication Publication Date Title
ZA201306944B (en) Individualized vaccines for cancer
HK1197182A1 (en) Cancer immunotherapy
EP2714073A4 (en) ANTI-CANCER ANTIGEN GENE VACCINE IN SITU
PL2758630T3 (pl) Regulowany system do szczelinowania
HK1199448A1 (en) Disubstituted 5-fluoro-pyrimidines 5--
IL231043A0 (en) vaccine
GB201120860D0 (en) Cancer immunotherapy
GB201119999D0 (en) Vaccine
HK1201176A1 (en) Antigen presenting cancer vaccine
EP2763699A4 (en) VACCINE
HK1202070A1 (en) Vaccine for tumor immunotherapy
ZA201306245B (en) Combination vaccines
EP2771453A4 (en) DIATOM-BASED VACCINES
ME03498B (me) Individualizovane vakcine protiv kancera
PL2729158T3 (pl) Szczepionki przeciwko Chlamydia
GB201120000D0 (en) Vaccine
GB201107549D0 (en) Cancer vaccine
GB201108982D0 (en) Vaccines
GB201108986D0 (en) Vaccines
GB201108984D0 (en) Vaccines
GB201121647D0 (en) Vaccine
GB201108256D0 (en) Vaccine